Creative Medical Technology Holdings, Inc.
CELZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.03 | 0.03 | -0.01 |
| FCF Yield | -13.60% | -16.94% | -37.03% | -51.11% |
| EV / EBITDA | -2.68 | -0.24 | 2.09 | 1.09 |
| Quality | ||||
| ROIC | -22.71% | -18.51% | -20.60% | -29.74% |
| Gross Margin | 0.00% | 0.00% | 60.00% | 60.00% |
| Cash Conversion Ratio | 0.95 | 0.94 | 0.97 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -37.52% | -56.64% | -42.49% | -50.11% |
| Free Cash Flow Growth | -0.85% | 27.19% | 18.36% | -97.80% |
| Safety | ||||
| Net Debt / EBITDA | 4.45 | 5.44 | 4.73 | 3.05 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 30.93 | 1.21 | 0.55 |
| Cash Conversion Cycle | 0.00 | -768.36 | -20,339.93 | -20,350.20 |